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S U M M A R Y
Objectives: To evaluate the susceptibility patterns among Streptococcus pneumoniae recovered during the
years 2010–2012 and to correlate these with serotypes.
Methods: Pneumococci from invasive sites were serotyped by sequential multiplex PCR and/or Quellung
reaction. Etest strips were used to determine the minimal inhibitory concentrations, and the Clinical and
Laboratory Standards Institute (CLSI) guidelines were used for interpretation. Genetic determinants of
macrolide resistance were assessed by PCR, and the occurrence of the D phenotype was analyzed
following the recommendations of the CLSI.
Results: One hundred ﬁfty-nine S. pneumoniae were studied; most were recovered from blood and were
associated with serotypes 14, 3, 4, 23F, 20, 7F, 12F, 19A, and 19F. Pneumococcal conjugate vaccine PCV7,
PCV10, and PCV13 and 23-valent polysaccharide vaccine serotypes represented 38.2%, 48.7%, 64.5%, and
85.5%, respectively. b-Lactam non-susceptibility (non-meningitis) was basically related to serotype 19A.
For meningitis, it was observed in 21.4% (serotypes 14, 3, 9V, 23F, and 24F). Resistance to erythromycin
occurred in 8.2% and mefA was the most common macrolide genetic determinant. One isolate was
resistant to levoﬂoxacin. Non-susceptibility to trimethoprim–sulfamethoxazole was 37.7% and to
tetracycline was 22.0%.
Conclusions: Our population of pneumococci represents a transition era, soon after the introduction of
PCV10. Non-susceptible patterns were found to be associated with classical PCV serotypes (especially
serotype 14), which is still highly prevalent, and non-PCV10 ones (19A), which may disseminate,
occupying the biological niche left by the vaccine serotypes.
 2013 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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The microbiological diagnosis of pneumococcal diseases is
frequently associated with challenging situations, such as the lack
of sensitivity of culture-related methodologies and the use of
antimicrobials prior to specimen collection.1 Thus, the ﬁnal
diagnosis is commonly based on clinical and epidemiological
characteristics of the disease, which results in empirical therapy.2* Corresponding author.
E-mail address: julianaca@ufcspa.edu.br (J. Caiera˜o).
1201-9712  2013 The Authors. Published by Elsevier Ltd on behalf of International S
http://dx.doi.org/10.1016/j.ijid.2013.11.009However, antimicrobial resistance among Streptococcus pneumo-
niae has become a subject of concern, and as a result, empirical
therapeutic choices may be compromised.3
Penicillin is the most important antibiotic against pneumo-
coccal diseases. Strains with decreased susceptibility to penicillin
were ﬁrst reported in the 1960s, and since that period, resistance
to this agent and other antimicrobials has been increasing
constantly, to various degrees, from one region to another.4–8
For the laboratory detection of penicillin and ceftriaxone
resistance, the Clinical and Laboratory Standards Institute (CLSI)
currently deﬁnes different breakpoints for meningitis and non-
meningitis isolates.9
Studies have reported that some resistance patterns may be
related to speciﬁc serotypes or clones, and the Pneumococcal
Molecular Epidemiology Network (PMEN) has described the mostociety for Infectious Diseases. Open access under CC BY-NC-SA license.
Table 1
Serotype distribution of 159 pneumococcal isolates from invasive infections; Porto
Alegre, Brazil, 2010–2012
Serotype Vaccine formulationa Number of isolates
Total 5 years
old
6 years
old
1 PCV10, PVC13, and PV23 3 - 3
3 PCV13 and PV23 13 2 11
4 PCV7, PCV10, PCV13,
and PV23
15 - 15
5 PCV10, PVC13, and PV23 2 - 2
6A PCV13 4 1 3
Serogroup 6 ? 1 - 1
6B PCV7, PCV10, PVC13,
and PV23
5 1 4
6C - 2 1 1
7C - 1 - 1
7F PCV10, PVC13,
and PV23
11 - 11
8 PV23 5 1 4
9A - 1 - 1
9N PV23 1 - 1
9V PCV7, PCV10, PVC13,
and PV23
6 - 6
10A PV23 1 - 1
11A PV23 4 - 4
12F PV23 11 - 11
14 PCV7, PCV10, PVC13,
and PV23
16 6 10
15B PV23 1 - 1
16F - 2 - 2
17F PV23 1 - 1
18A - 1 - 1
18C PCV7, PCV10, PVC13,
and PV23
1 - 1
19A PVC13, and PV23 7 1 6
19F PCV7, PCV10, PVC13,
and PV23
5 2 3
20 PV23 12 - 12
22F PV23 1 - 1
23F PCV7, PCV10, PVC13,
and PV23
10 1 9
24F - 4 - 4
28A - 1 - 1
34 - 1 - 1
35F - 2 - 2
38 - 2 1 1
Non-typeable - 3 - 3
Not available for
serotyping
- 3 - 3
Total 159 17 142
a PCV 7, 10, and 13 = pneumococcal conjugated vaccine with 7, 10, and 13
serotypes; PV23 = 23-valent polysaccharide vaccine.
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in penicillin non-susceptibility in the USA following the introduction
of the 7-valent pneumococcal conjugate vaccine (PCV7), which was
strongly associated with the dissemination of serotype 19A, is a good
example of the clone–resistance pattern correlation.11
The introduction of different formulations of conjugate vaccines,
as well as other variables, has contributed to changes in antimicro-
bial resistance worldwide.8 In Brazil, a 10-valent vaccine (PCV10)
has been introduced for children aged less than 2 years as part of the
national program of immunization; however its effect on serotype
distribution and antimicrobial resistance in this country are yet to be
determined. As the diversity of serotypes and the increasing
resistance to antibiotics are two essential elements that must be
taken into account for the prevention and management of
pneumococcal infections,5,12 the objective of the present study
was to evaluate the susceptibility patterns among S. pneumoniae
recovered during the years 2010–2012 and to correlate these with
serotypes.
2. Materials and methods
2.1. Bacterial isolates
A total of 159 non-duplicate S. pneumoniae isolates were
included in the study. They were isolated from January 2010 to
April 2012 in three general hospitals in Porto Alegre, Brazil. The
study included isolates from patients with invasive pneumococcal
diseases (IPD). The isolates were maintained at 80 8C and the
species identiﬁcation was done by routine tests: colony morphol-
ogy, optochin susceptibility, and sodium deoxycholate lysis.13
2.2. Serotyping
Isolates were serotyped using a sequential multiplex PCR14
targeting the 30 most common serotypes related to IPD in Latin
America plus the capsular polysaccharide (cps) gene. For most
isolates that presented ampliﬁcation of only the cps gene, the
Quellung reaction was performed using pool-, type-, and factor-
speciﬁc antisera kindly provided by the US Centers for Disease
Control and Prevention (CDC).
2.3. Susceptibility tests
Etest strips (AB Biodisk, Stockholm, Sweden) were used to
determine the minimal inhibitory concentration (MIC), following
the manufacturer’s instructions. MICs for penicillin, ceftriaxone,
vancomycin, meropenem, erythromycin, levoﬂoxacin, tetracycline,
and trimethoprim–sulfamethoxazole were evaluated. Interpreta-
tion of the results was done in accordance with the CLSI guidelines
(2013),9 taking into account the site of isolation to set the penicillin
and ceftriaxone susceptibilities. Etest MICs were rounded up to a
standard two-fold agar dilution scale. The reference strain S.
pneumoniae ATCC 49619 was used for quality control.
2.4. Inducible resistance to clindamycin
To determine the erythromycin inducible resistance to clinda-
mycin, isolates presenting resistance to erythromycin and suscepti-
bility or intermediate resistance to clindamycin were submitted to
D-zone test, following the 2013 CLSI recommendations.9
2.5. Genetic determinants of macrolide resistance
Isolates presenting a MIC 0.5 mg/ml for erythromycin were
submitted to a duplex PCR reaction for the detection of the ermB
and mefA genes, in accordance with Widdowson and Klugman.15Brieﬂy, approximately 100 ng of DNA were used as template in a
20-ml reaction with 0.75 mM of each primer and 2 U of Taq DNA
polymerase, at an annealing temperature of 56 8C. PCR products
were visualized on a 2% TBE (Tris–borate–ethylenediaminetetraa-
cetic acid (EDTA)) agarose gel, containing 0.5 mg/ml of ethidium
bromide.
3. Results
We studied 159 S. pneumoniae isolates obtained from invasive
sites, including blood (n = 124), cerebrospinal ﬂuid (CSF) (n = 28),
pleural ﬂuid (n = 5), peritoneal ﬂuid (n = 1), and joint ﬂuid (n = 1).
Patients ranged in age from 0 to 94 years, with an average of 47.9
years. Seventeen patients (10.7%) were aged 5 years and 39
(24.5%) were aged 65 years. Age was not available in the records
for 13 patients and three others were identiﬁed as ‘pediatric’
without a deﬁned age.
The distribution of serotypes found among isolates (in general
and stratiﬁed by age) is shown in Table 1. Three isolates could not
Table 2
Prevalence of resistance and the MIC50 and MIC90 among 159 invasive pneumococcal isolates; Porto Alegre, Brazil, 2010–2012
Susceptibility MIC
R (%) I (%) S (%) MIC50 (mg/ml) MIC90 (mg/ml)
Penicillin (non-meningitis) 0 1 (0.6) 158 (99.4) 0.025 1
Ceftriaxone (non-meningitis) 0 2 (1.3) 157 (98.7) 0.016 0.5
Meropenem 1 (0.6) 6 (3.8) 152 (95.6) 0.006 0.25
Erythromycin 13 (8.2) 0 146 (91.8) 0.125 0.25
Tetracyclineb 30 (19) 5 (3.2) 123 (77.8) 0.25 16
Levoﬂoxacin 1 (0.63) 0 158 (99.4) 1 1
Trimethoprim–sulfamethoxazole 32 (20.1) 28 (17.6) 99 (62.3) 0.25 4
MIC, minimal inhibitory concentration; R, resistant; I, intermediate; S, susceptible.
a Statistically signiﬁcant.
b One isolate was not available for tetracycline testing.
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6 (according to the sequential multiplex PCR procedure) was not
available for Quellung reaction. A total of 33 different serotypes
were identiﬁed. Isolates belonging to serotypes 14 (n = 16), 4
(n = 15), 3 (n = 13), 20 (n = 12), 7F (n = 11), 12F (n = 11), 23F
(n = 10), 19A (n = 7), 9V (n = 6), 6B (n = 5), and 19F (n = 5) were the
most frequently found. Three isolates were deﬁned as non-
typeable by Quellung reaction. Serotypes included in the 7-, 10-,
and 13-valent conjugate vaccines and the 23-valent polysaccha-
ride vaccine represented 38.2% (n = 58), 48.7% (n = 74), 64.5%
(n = 98), and 85.5% (n = 130), respectively, of the 152 isolates with a
deﬁned serotype. Among children aged 5 years (n = 17), serotype
14 was again the most common, but at this time more
representative (35.5% vs. 7.0% in the population >5 years old).
Vaccine coverage in this group was 58.8%, 58.8%, and 82.3% for the
7-, 10-, and 13-valent conjugate vaccines, respectively. In the even
more restrictive group (under 2 years of age, n = 12), the vaccine
coverage was 58.3%, 58.3%, and 83.3%. Taking into account people
aged 65 years, these numbers decreased further: 30.8% (12/39),
33.3% (14/39), and 41.0% (18/40) for the 7-, 10-, and 13-valent
conjugate vaccines, respectively. However, the polysaccharide
vaccine (PPV23) had 71.8% coverage in this speciﬁc population.
Table 2 presents the prevalence of resistance and the MIC50 and
MIC90 for the 159 pneumococcal isolates. One isolate was not
available for tetracycline testing. Regardless of resistance rates, the
most potent drugs against pneumococci were meropenem and
erythromycin (MIC90 = 0.25 mg/ml). All isolates were susceptible toTable 3
Characteristics of isolates presenting resistance to penicillin (intermediate, non-menin
meropenem (intermediate or full resistance)
Isolate number Serotype Specimen Patient age (years) MIC
PEN
033.12 14 Blood 27 2 
008.11 14 Blood Pediatric 1 
112.11 14 Pleural ﬂuid 2 0.5 
162.11 14 blood 4 1 
164.11 14 blood 4 1.5 
025.12 19A Blood 67 4 
167.11 19A Blood 67 2.0 
MIC, minimal inhibitory concentration; PEN, penicillin; CRO, ceftriaxone; MER, merope
Table 4
Distribution of the genes involved among the 13 erythromycin-resistant isolates, serot
Genes involved n Serotypes (number in parenthes
mefA 6 14 (5), 19A, non-typeable (1) 
ermB 4 6B (1), 19F (1), 23F (1), 24F (1) 
mefA + ermB 3 19A (2), 19F (1) 
MIC, minimal inhibitory concentration.penicillin and ceftriaxone (non-meningitis breakpoints); however,
intermediate resistance was found to penicillin (one isolate) and
ceftriaxone (two isolates), all isolates serotyped as 19A. Considering
the meningitis breakpoint (0.125 mg/ml), resistance to penicillin
was observed in 6/28 (21.4%) isolates obtained from CSF, belonging
to the following serotypes: 14 (two isolates), 3, 9V, 23F, and 24F (one
isolate each). All CSF isolates were susceptible to ceftriaxone
(meningitis breakpoint). Characteristics of pneumococci presenting
resistance to penicillin (intermediate, non-meningitis), to ceftriax-
one (intermediate or full, meningitis or non-meningitis), and to
meropenem (intermediate or full resistance), the serotypes, and
resistance to other antimicrobials are detailed in Table 3. Penicillin
MICs higher than 0.06 mg/ml were more frequently associated with
serotypes 14 (32.0%), 23F (12.0%), 9V (12.0%), 19A (8.0%), and 19F
(6.0%), representing 70.0% of all cases.
Resistance (MIC 1 mg/ml) to erythromycin was observed in
8.2% (13/159) of the isolates. The mefA gene alone was ampliﬁed in
6/13 (46.1%) and the ermB gene alone in 4/13 (30.8%) pneumococ-
ci; both genes were ampliﬁed in 3/13 (23.0%). The presence of ermB
(alone or with mefA) was associated with a MIC 256 mg/ml.
Table 4 shows the distribution of genes involved in erythromycin
resistance, the results of the D-test, and serotypes found among
THESE pneumococci.
Isolates were fully susceptible to vancomycin (MIC50 and
MIC90 = 0.5 mg/ml). Only one S. pneumoniae, isolated from a blood
culture, was resistant to levoﬂoxacin, with a MIC of 16 mg/ml; this
isolate belonged to serotype 23F. Higher levels of non-susceptibilitygitis), to ceftriaxone (intermediate or full, meningitis or non-meningitis), and to
 (mg/ml) ermB gene mefA gene
 CRO MER ERY TET
1 0.5 0.047 0.125 ND ND
0.5 0.5 24 0.125 Neg Pos
0.5 0.5 24 0.25 Neg Pos
0.5 0.5 16 <0.25 Neg Pos
0.5 0.5 8 1 Neg Pos
2 1 >256 6 Pos Pos
2 0.5 >256 8 Pos Pos
nem; ERY, erythromycin; TET, tetracycline; ND, not done.
ypes found, minimal inhibitory concentrations, and results of the D-test
is) MIC or MIC range (mg/ml) D-test results
1.5–24 Neg
>256 Neg (2); Pos (2)
>256 Pos
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intermediate and 17.6% resistant) and tetracycline (22.0%: 18.9%
intermediate and 3.1% resistant).
4. Discussion
Pneumococcal disease is a global public health problem,
especially in developing countries. In these regions, epidemiologi-
cal surveillance focusing on the serotype distribution and
resistance proﬁles of pneumococci is of great importance to
reduce the burden of the disease and to improve therapy. A
comprehensive understanding of antimicrobial resistance and the
inﬂuence of serotypes on the susceptibility proﬁles should be
obtained from investigations with pneumococci gathered from
different parts of the world. In this context, the present study
generated epidemiological data on the pneumococci circulating in
the South of Brazil, taking into account the occurrence of
antimicrobial resistance and its correlation with serotypes.
Many studies around the world have demonstrated an
increasing trend in resistance of pneumococci to various classes
of antimicrobials,4–8,12 both in regions where a conjugated vaccine
is available and efﬁciently provided to the population,8 and where
there is no active public vaccination program.5 In the former
context, the fact is possibly explained by the replacement of
vaccine serotypes with others, which may present worrying
resistance rates; serotype 19A is a classical example. In the second
group, the reduced susceptibility may be especially related to the
circulation of vaccine serotypes typically associated with antimi-
crobial resistance, such as 14, 19F, and 23F. Therefore, regardless of
the existence or not of a vaccination program, resistance among
pneumococci is becoming a matter of concern.
Our pneumococci represent post-vaccination isolates. Howev-
er, considering that our study population consisted mostly of
adults, we may expect the ﬁndings to represent a transition era, i.e.,
not enough time has elapsed to observe the effects of vaccination
(herd immunity) on the adult population. Indeed, almost half
(47.4%) of our pneumococcal isolates represented PCV10 sero-
types, while the remaining isolates represented mixed non-PCV10
ones. According to Afonso et al.,16 vaccine coverage in Porto Alegre
is around 80%, which is lower than in other cities of Brazil.
Altogether, these data support this being a transitional period.
Dos Santos et al.17 ﬁrst evaluated the distribution of serotypes
among invasive disease before and after the implementation of
PCV10 in Brazil. As expected, the incidence of PCV10 serotypes
decreased in a comparison of the two periods, although the
reduction was statistically signiﬁcant only for the population aged
<2 years. This reinforces the concept that a longer period of time
needs to elapse from the implementation of PCV10 to observe its
effect on the adult population (transition period). Among PCV10
serotypes, 14, 1, 5, and 7F were in the group of serotypes with a
higher incidence during both periods observed by Dos Santos et al.
Regarding non-PCV10 serotypes, 19A, 3, and 12F were predomi-
nant in this group. Although these data are from a different
geographical region of Brazil, our serotype distribution results are,
in general, consistent with those observed in that study. Our
isolates present a wide distribution of serotypes, which include
members of the different vaccine formulations, but 17.7% of them
are not included in the most comprehensive of the vaccines, PPV23.
Among children (age 5 years), the proportion of isolates
belonging to serotypes included in the vaccine (PCV10) was lower
compared to values observed in other Brazilian studies (58% vs.
75.7–80%17,18). However, it is necessary to note that our data are
derived from a relatively limited number of isolates, which
compromises the interpretation of the results.
With regard to our general population, PCV10 coverage was
even lower. This may be explained in part by the circulation ofserotypes not related to PCV10, such as 12F, 7F, 20, and 19A.
Attention should be drawn to the fact that serotypes such as 12F
and 20, which were among the six most frequent, are not included
in the available conjugate vaccines. This highlights the possibility
of the emergence of these serotypes in the future.
In general, our resistance rates are lower than those observed in
other countries with vaccination programs.6,8,19 In groups where
there is no active vaccination, or where vaccine coverage is not
wide, resistance rates have also been higher than ours. In these
cases, the most common serotypes recovered have been 14, 23F,
6B, and 19F, classical PCV7 ones.4,5 In Latin America, knowledge of
the circulating pneumococci is limited. Data from the SIREVA
project, connected to the Pan American Health Organization, have
shown reduced susceptibility to penicillin in 38% of isolates, with
an increasing trend in some countries, including Brazil.20 Data
from Brazil are still scarce and fragmented. Some studies have
shown low21,22 or no23 rates of non-susceptibility to penicillin,
whereas others have indicated rates around 20%;24–25 serotypes
14, 23F, 6B, and 19F have been most commonly associated with
this resistance in brazilian studies.24,25
Full resistance (MIC >4.0 mg/ml) to penicillin was not found
among the isolates included in this study. However, pneumococci
showing intermediate or full resistance to b-lactams were
observed, and this was associated with serotypes 14 and 19A.
The characteristics of patients are distinct among those with
serotype 14 and 19A. Patients with infection due to resistant
serotype 14 isolates were younger (four children and one aged 27
years), whereas patients with 19A infections were older (>65
years). Also, b-lactam-resistant isolates of serotype 14 were
resistant to erythromycin due to the presence of the mefA gene,
while those belonging to serotype 19A harbored the ermB gene and
had higher erythromycin MICs (>256 mg/ml). Both of these
serotypes contain clones associated with resistance that are
internationally distributed, such as sequence types ST156 (sero-
type 14) and ST320 (serotype 19A). While serotype 14 has
historically (pre-vaccination period) been associated with penicil-
lin resistance, with ST156 distributed worldwide including in
Brazil,25 many studies in the post-vaccination era have pointed to
the important relationship between 19A and penicillin non-
susceptibility.8,18,26
As noted above, among patients infected with non-susceptible
serotype 14 pneumococci, four out of ﬁve were children, one of
them without a deﬁned age (‘pediatric’). Two of them were 4 years
old at the time of specimen collection (2011), which suggests that
these patients did not receive the 2010 PCV10 immunization. The
remaining patients were 2 years old (2011). These data may
explain the occurrence of resistant serotype 14 among our
pediatric population. However, as the number of children included
in the study was low, statistical power is lacking to support
information considering serotype distribution and antimicrobial
susceptibility characteristics in this speciﬁc age group.
Another important therapeutic choice for pneumococcal
infections is the macrolides. Resistance to erythromycin varies,
in general from 25% to near 50%.4,5,8 However, rates as high as 92%
have been reported in some regions.6 As shown by Mendonc¸a-
Souza et al.27 in a large prospective study of isolates from three
major cities in Brazil, pneumococci belonging to serotype 19A have
been circulating in our region since 1996, recovered particularly
from non-invasive sites and presenting resistance to erythromycin,
tetracycline, and penicillin (previous 2008 CLSI breakpoints).
Vaccination may provide conditions for the emergence of non-
PCV10 serotypes, such as 19A. Further studies involving genotyp-
ing and clonality are necessary to better determine the inﬂuence of
such speciﬁc clones on antibiotic resistance in Brazil. It is also
important to highlight the occurrence of isolates exhibiting both
ermB and mefA genes among serotypes 19A and 19F.
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one isolate with intermediate resistance was observed among
invasive and non-invasive pneumococci. Similar results were
found in the current study (one fully resistant isolate) and by
another group of authors in Latin America.28 Although our data are
also in agreement with those of other Brazilian studies with regard
to tetracycline resistance (between 20% and 30%), some authors
have shown higher trimethoprim–sulfamethoxazole resistance
rates (up to 60%) in other regions of the country.24,25
Our study has some limitations. As we did not have a pre-
vaccination population, we were unable to evaluate the impact of
vaccination on resistance rates in our region. We also emphasize
that serotyping the strains before starting a vaccination campaign
is highly recommended for future experience. Also, as mentioned,
our population included a small number of patients less than 5
years of age. Thus, we were not able to evaluate the initial effects of
the vaccination appropriately, once children became the target for
ﬁrst-stage processing.
Nevertheless, our data provide important information on the
susceptibility proﬁle of pneumococci soon after the introduction of
the vaccination. To our knowledge, this is among the ﬁrst works to
provide information on the pneumococcal serotype distribution
following implementation of vaccination in Brazil. Our data show
the occurrence of non-susceptibility to penicillin and other b-
lactams among serotypes 14 and 19A. It is expected that the
ﬁnding of serotype 14 in invasive disease will be massively
reduced as the effect of PCV10 is increasingly observed. On the
other hand, because serotype 19A is not included in the current
vaccine formulation, non-susceptible isolates may increase in our
region. In this context, epidemiological studies should be done
systematically to evaluate the long-term effects of vaccination on
serotype distribution and how changes in the distribution of
serotypes in the post-vaccination era will impact resistance rates
in the pneumococcal population.
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